Floatz logo

Fludarabine

T(14;20)

Institute of Hematology & Blood Diseases Hospital, ChinaSmall moleculeN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the T(14;20) cohort.

Asset / SponsorPhaseRating
Evomela
Institute of Hematology & Blood Diseases Hospital, China
N/AD
DEXAMETHASONE
Institute of Hematology & Blood Diseases Hospital, China
N/AD
Bortezomib
Institute of Hematology & Blood Diseases Hospital, China
N/AD

Same molecule, other indications

Fludarabine is also rated in:

acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
76 / 100
View asset →
Fanconi anemiaDormant
BBB
Indicative ·
76 / 100
View asset →
Recurrent Adult Diffuse Large Cell LymphomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →